Screener
CRISPR Therapeutics CRSP Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's debt-to-equity?
- CRISPR Therapeutics (CRSP) reported debt-to-equity of 0.4× in Q1 2026.
- How has CRISPR Therapeutics's debt-to-equity changed year-over-year?
- CRISPR Therapeutics's debt-to-equity increased by 262.1% year-over-year, from 0.1× to 0.4×.
- What is the long-term trend for CRISPR Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's debt-to-equity has grown at a 23.9% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about CRISPR Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude